• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Friday 07/20/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Black Label

  • 4:44 PM

    Jan 14, 2016, MSLP,  OTC Disclosure & News Service – MusclePharm Corporation (OTCQB: MSLP) (“MusclePharm” or the “Company”), a scientifically-driven, performance lifestyle sports nutrition company, today announced the completion of a financing agreement with Prestige Capital Corporation (“Prestige Capital”) in the initial amount of $10 million. The financing agreement is a major step towards strengthening the Company’s financial position. The agreement with Prestige Capital allows the Company to use its receivables to finance up to a total of $10 million. The Company

    Read more
  • 3:21 PM

    SILVER SPRING, Md., Jan. 14, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial

    Read more
  • 3:13 PM

    SILVER SPRING, Md., Jan. 04, 2016, PMCB, (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as

    Read more
  • 2:50 PM

    SILVER SPRING, Md., Sep 18, 2014 (GLOBE NEWSWIRE via COMTEX) — Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today provides its shareholders with an update on recent activities of Nuvilex and outlines future plans for the development of treatments in the areas of cancer and diabetes. Pancreatic Cancer Nuvilex currently holds the exclusive, worldwide rights to use the Cell-in-a-Box cellulose-based live cell encapsulation technology for the development of a

    Read more
  • 1:02 PM

      MONTREAL, QC, Apr 29, 2014 (Marketwired via COMTEX) — Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has entered into an Investment Agreement with Dutchess Opportunity Fund, II, LP (“Dutchess”). Dutchess has agreed to purchase up to $2.5 million of shares of Sunshine’s Common Stock over a three-year commitment period. Under the terms of the Investment Agreement Sunshine

    Read more
  • 2:59 PM

    http://www.publicwire.comNuvilex Retains TD2 to Conduct Preclinical and Clinical Studies SILVER SPRING, Apr 01, 2014 (GLOBE NEWSWIRE via COMTEX) — Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex’s pancreatic cancer and other treatments utilizing Cell-in-a-Boxtechnology. “The Nuvilex team

    Read more
Public Wire Banner